Mariano Andrés1,2, Francisca Sivera3, Eliseo Pascual4. 1. Sección de Reumatología, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Hospital General Universitario de Alicante, Pintor Baeza 12, 03010, Alicante, Spain. drmarianoandres@gmail.com. 2. Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain. drmarianoandres@gmail.com. 3. Sección de Reumatología, Hospital General Universitario de Elda, Alicante, Spain. 4. Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Universidad Miguel Hernández, Alicante, Spain.
Abstract
PURPOSE OF REVIEW: Current evidence and accumulated experience for the management of calcium pyrophosphate deposition disease (CPPD) are presented. RECENT FINDINGS: Contrary to other rheumatic inflammatory conditions that account for high interest and growing research, advances in treating CPPD are still very limited and mostly derive from those achieved in gout. Once formed, calcium pyrophosphate crystals cannot be dissolved; therefore, management relies on the control of crystal-derived inflammation. Besides classical agents-such as colchicine, glucocorticoids, or NSAIDs-the use of targeted therapies, mostly against interleukin-1, has provided a relevant relief for refractory CPPD patients in recent years. Meanwhile, former enthusiasm about conventional disease-modifying agents such as methotrexate is currently controversial.
PURPOSE OF REVIEW: Current evidence and accumulated experience for the management of calcium pyrophosphate deposition disease (CPPD) are presented. RECENT FINDINGS: Contrary to other rheumatic inflammatory conditions that account for high interest and growing research, advances in treating CPPD are still very limited and mostly derive from those achieved in gout. Once formed, calcium pyrophosphate crystals cannot be dissolved; therefore, management relies on the control of crystal-derived inflammation. Besides classical agents-such as colchicine, glucocorticoids, or NSAIDs-the use of targeted therapies, mostly against interleukin-1, has provided a relevant relief for refractory CPPD patients in recent years. Meanwhile, former enthusiasm about conventional disease-modifying agents such as methotrexate is currently controversial.
Authors: Daniel H Solomon; M Elaine Husni; Peter A Libby; Neville D Yeomans; A Michael Lincoff; Thomas F Lϋscher; Venu Menon; Danielle M Brennan; Lisa M Wisniewski; Steven E Nissen; Jeffrey S Borer Journal: Am J Med Date: 2017-07-26 Impact factor: 4.965
Authors: Axel Finckh; Geraldine M Mc Carthy; Anne Madigan; Daniel Van Linthoudt; Marcel Weber; David Neto; Georges Rappoport; Sandra Blumhardt; Diego Kyburz; Pierre-Andre Guerne Journal: Arthritis Res Ther Date: 2014-10-15 Impact factor: 5.156
Authors: Dinesh Khanna; Puja P Khanna; John D Fitzgerald; Manjit K Singh; Sangmee Bae; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub Journal: Arthritis Care Res (Hoboken) Date: 2012-10 Impact factor: 4.794
Authors: W Zhang; M Doherty; E Pascual; V Barskova; P-A Guerne; T L Jansen; B F Leeb; F Perez-Ruiz; J Pimentao; L Punzi; P Richette; F Sivera; T Uhlig; I Watt; T Bardin Journal: Ann Rheum Dis Date: 2011-01-20 Impact factor: 19.103
Authors: W Zhang; M Doherty; T Bardin; V Barskova; P-A Guerne; T L Jansen; B F Leeb; F Perez-Ruiz; J Pimentao; L Punzi; P Richette; F Sivera; T Uhlig; I Watt; E Pascual Journal: Ann Rheum Dis Date: 2011-01-07 Impact factor: 19.103
Authors: Georg Theiler; Franz Quehenberger; Franz Rainer; Manfred Neubauer; Mariana Stettin; Christoph Robier Journal: Rheumatol Int Date: 2012-12-27 Impact factor: 2.631
Authors: Francesca Oliviero; Yessica Zamudio-Cuevas; Elisa Belluzzi; Lisa Andretto; Anna Scanu; Marta Favero; Roberta Ramonda; Giampietro Ravagnan; Alberto López-Reyes; Paolo Spinella; Leonardo Punzi Journal: Foods Date: 2019-11-07